ADJUVANTS--TYROSINE DERIVATIVES AND CONTROLLED RELEASE
Project Number5U01AI025901-02
Contact PI/Project LeaderLANGER, ROBERT SAMUEL
Awardee OrganizationMASSACHUSETTS INSTITUTE OF TECHNOLOGY
Description
Abstract Text
The controlled release of marcomolecules from inert polymeric
martix devices has been extensively researched by our group.
Furthermore, a recently synthesized class of bioerodible
polymers, made from the non-peptide linking of typrosine
dipeptide derivatives, demonstrates adjuvanticity in both
monomeric and polymeric form. The aim of the proposed
research is to develop a controlled release immunization implant
which will have a two-fold effect. First, the device will produce
sustained, controlled release of antigen in vivo, thereby initiating
production of antibody specific for that antigen and successfully
immunizing the animal. Second, the products formed during
polymer hydrolysis will have an adjuvant effect on the immune
response, thus enhancing the level and duration of antibody
production and improving protection against subsequent challenge.
To achieve this goal:
1) Poly(iminocarbonates) composed of N- and C-blocked
derivatives of N-(L-tyrosyl)-L-tyrosine will be synthesized and
characterized with regard to molecular weight mechanical
properties, surface properties, and degradation behavior;
2) The release of model antigens from devices composed of these
polymers will be measured and mathematically modelled;
3) Adsorption-desorption studies of polymer and antigen will be
conducted to investigate the "depot" effect mechanism of
adjuvanticity;
4) Polymeric devices containing antigen and polymer-antigen
adsorbates will be implanted or injected in mice, and the antigen-
specific antibody levels will be measured by ELISA; and
5) Release patterns from devices will be altered with ultrasound
or formulation parameters to determine the effect of dosage on
adjuvanticity.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
001425594
UEI
E2NYLCDML6V1
Project Start Date
30-September-1987
Project End Date
31-August-1990
Budget Start Date
01-September-1988
Budget End Date
31-August-1989
Project Funding Information for 1988
Total Funding
$161,350
Direct Costs
$98,988
Indirect Costs
$62,362
Year
Funding IC
FY Total Cost by IC
1988
National Institute of Allergy and Infectious Diseases
$161,350
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U01AI025901-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U01AI025901-02
Patents
No Patents information available for 5U01AI025901-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U01AI025901-02
Clinical Studies
No Clinical Studies information available for 5U01AI025901-02
News and More
Related News Releases
No news release information available for 5U01AI025901-02
History
No Historical information available for 5U01AI025901-02
Similar Projects
No Similar Projects information available for 5U01AI025901-02